Multiple myeloma incidences are increasing across the globe and presently available therapeutics are unable to offer effective clinical benefits. Multiple myeloma chemotherapeutics shows modest pharmacological efficacy due to which necessity for better options are required. Surgery and radiation are equally ineffective and they are not viable for most of the cases. Pharmaceutical companies have identified this scenario due to which they are investing more funds in research and development segment. As a result, investigators would be able to screen more lead molecules for their safety and efficacy in multiple myeloma. Innovative modalities are being studied in clinical trial and they are expected to yield significant results thereby surpassing the issues related with presently available modalities in coming years.

In past few decades several methods for treatment of multiple myeloma has been developed by investigators. Surgery could be performed for transplanting bone marrow from healthy donor. Radiation therapy has modest effect because myeloma cells are spread throughout the body which means higher dosage are required. Chemotherapeutics have been used successfully in past few decades for multiple myeloma treatment. New modalities are being tried by investigators to decrease its morbidity and mortality rates. They are also expected to have lesser side effects and would be able to increase average survival rates. Several innovative multiple myeloma therapeutics is available in market which offers higher safety and efficacy levels. It is expected that new innovative therapeutics would be able to offer better pharmacological benefit to patients and generate significant revenues in coming years.

Stem cell transplant has been suggested by investigators as an effective way to treat multiple myeloma. These cells have capability to differentiate according to the environment in which they have been place. External cues can also be used to transform them into desired type before implanting in the body. Some researchers have proposed the use of recombinant proteins to be implanted in the bone marrow which will prevent the proliferation of multiple myeloma. More time is required to develop and refine this technology which could potentially eliminate multiple myeloma from the body. Such technologies are still under different phases of development and they are expected to take some time before entering in global market. These modalities are expected to change the way multiple myeloma is treated but lots of progress has yet to be made by investigators.

Monoclonal antibodies (mAbs) have been successfully used for the several malignancies due to their superior therapeutic efficacy and high specificity. Targeted mAbs have the ability to bind to specific cells due to which minimized side effects are observed in cancer patients. Investigators are also trying to develop targeted mAbs for treating multiple myeloma which would be offer better therapeutic effects. New modalities like cancer vaccines are also under investigation for studying their pharmacological efficacy. Vaccines for multiple myeloma are under investigation and they are expected to overcome relapse because they activates the patient's immune system. Important part of developing such vaccines is to carefully choose the correct candidate for long-term efficacy. They are also at different stages of clinical trials and strong clinical data is required before their marketing approval in coming years.

Several new developments are expected to take place in field of multiple myeloma segments in coming years. Technological advancements along with rising funding levels is expected to increase the rate of innovations for the development of multiple myeloma drug. As a result, their pipeline is expected to become strong and more clinical trials across the globe are expected to be instigated. Positive outcomes are expected from these clinical trials due to which volume of multiple myeloma therapeutics is going to increase. Simultaneously, there sales are also expected to increase due to profit erosion of presently available therapeutics. In this way, newly introduced multiple myeloma therapeutics are expected to increase several folds in coming years. Besides this, more patients are willing to pay for such therapeutics which can increase their disease free progression.

"Global Multiple Myeloma Drug Market & Pipeline Insight 2015" Report Highlight:
- Global Multiple Myeloma Drug Market Analysis
- Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase
- Marketed Multiple Myeloma Drugs Clinical Insight
- Mechanism of Multiple Myeloma Drug
- Global Multiple Myeloma Drug Clinical Pipeline: 164 Drugs
Majority Multiple Myeloma Drugs in Phase-II Trials: 40
Marketed Multiple Myeloma Drugs: 9

Contents:

1. Introduction to Multiple Myeloma
2. Mechanism of Multiple Myeloma Drug
3. Global Multiple Myeloma Drug Market Analysis
   3.1 Current Market Scenario
   3.2 Multiple Myeloma Drug Clinical Pipeline Overview
4. Global Multiple Myeloma Drug Market Dynamics
   4.1 Favorable Market Parameters
   4.2 Commercialization Challenges
5. Global Multiple Myeloma Drug Market Future Prospects
6. Global Multiple Myeloma Drug Clinical Insight by Company, Indication & Phase
   6.1 Research
   6.2 Preclinical
   6.3 Clinical
   6.4 Phase-I
   6.5 Phase-I/II
   6.6 Phase-II
   6.7 Phase-III
   6.8 Preregistration
7. Marketed Multiple Myeloma Drugs Clinical Insight
   7.1 Bendamustine (Innomustine® Levact®, Treanda® & Treakisym®)
   7.2 Bortezomib (Velcade®)
   7.3 Carfilzomib (Kyprolis®)
   7.4 Doxorubicin Liposomal - ALZA
   7.5 Interferon Alpha-2b (Intron® A)
   7.6 Lenalidomide (Ladevina® & Revlimid®)
   7.7 Pomalidomide (Imnovid® & Pomalyst®)
   7.8 Thalidomide (Thaled®, Thalidomide Celgene™ & Thalomid®)
   7.9 Zoledronic Acid (Zometa®)
8. Discontinued & Suspended Multiple Myeloma Drugs in Clinical Pipeline
   8.1 No Development Reported
   8.2 Discontinued
   8.3 Suspended
9. Competitive Landscape
   9.1 AbbVie
   9.2 Altor BioScience
   9.3 Astellas Pharma
   9.4 Astex Pharmaceuticals
   9.5 Benovus Bio
   9.6 Biogen Idec
   9.7 Bristol-Myers Squibb
   9.8 Celegen Pharmaceuticals
   9.9 Cleave Biosciences
   9.10 Genmab
   9.11 Novartis
   9.12 Onyx Pharmaceuticals
   9.13 Pfizer
   9.14 Millennium Pharmaceuticals
   9.15 Vaxil Biotherapeutics

List of Figures:
*Figure 1-1: Type of Blood Cancer
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to 646-607-1907 (from USA) or +353-1-481-1716 (from Rest of World). If you have any questions please visit http://www.researchandmarkets.com/contact/

Order Information
Please verify that the product information is correct and select the format(s) you require.

Product Name: Global Multiple Myeloma Drug Market & Pipeline Insight 2015
Web Address: http://www.researchandmarkets.com/reports/3218382/
Office Code: SCBRONN8

Product Formats
Please select the product formats and quantity you require:

<table>
<thead>
<tr>
<th>Format</th>
<th>Quantity</th>
<th>Price</th>
</tr>
</thead>
<tbody>
<tr>
<td>Electronic (PDF) - Single User</td>
<td></td>
<td>USD 1800</td>
</tr>
<tr>
<td>Hard Copy</td>
<td></td>
<td>USD 2400 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>CD-ROM</td>
<td></td>
<td>USD 2400 + USD 58 Shipping/Handling</td>
</tr>
<tr>
<td>Electronic (PDF) - Enterprisewide</td>
<td></td>
<td>USD 3600</td>
</tr>
</tbody>
</table>

* Shipping/Handling is only charged once per order.

Contact Information
Please enter all the information below in BLOCK CAPITALS

Title: [ ] Mr [ ] Mrs [ ] Dr [ ] Miss [ ] Ms [ ] Prof
First Name: ___________________________ Last Name: ___________________________
Email Address: * ___________________________
Job Title: ___________________________
Organisation: ___________________________
Address: ___________________________
City: ___________________________
Postal / Zip Code: ___________________________
Country: ___________________________
Phone Number: ___________________________
Fax Number: ___________________________

* Please refrain from using free email accounts when ordering (e.g. Yahoo, Hotmail, AOL)
Payment Information

Please indicate the payment method you would like to use by selecting the appropriate box.

☐ Pay by credit card: You will receive an email with a link to a secure webpage to enter your credit card details.

☐ Pay by check: Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Center,
Taylors Lane,
Dublin 8,
Ireland.

☐ Pay by wire transfer: Please transfer funds to:

Account number 833 130 83
Sort code 98-53-30
Swift code ULSBIE2D
IBAN number IE78ULSB98533083313083
Bank Address Ulster Bank,
27-35 Main Street,
Blackrock,
Co. Dublin,
Ireland.

If you have a Marketing Code please enter it below:

Marketing Code: __________________________

Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 - From USA
+353-1-481-1716 or +353-1-653-1571 - From Rest of World